20/20 BioLabs Expands Access to OneTest Cancer via 40,000 Practitioners
20/20 BioLabs’ OneTest for Cancer is now available through Evexia Diagnostics’ platform, granting access to over 40,000 functional and integrative medicine practitioners nationwide. Evexia selected OneTest for its affordability, strong early-stage cancer sensitivity and biomarker quantification capabilities that enable personalized patient monitoring.
1. Partnership Details
20/20 BioLabs has partnered with Evexia Diagnostics to offer its OneTest for Cancer through Evexia’s ordering platform, enabling more than 40,000 functional and integrative medicine practitioners to access the test within existing clinical workflows.
2. Test Features
Evexia selected OneTest for its combination of affordability and high sensitivity in detecting early-stage cancers, along with its ability to identify and quantify specific biomarkers for personalized baseline creation and ongoing health tracking.
3. Commercial Impact
This collaboration is expected to boost 20/20 BioLabs’ market penetration and drive commercial growth by broadening test visibility and adoption among a large network of specialty practitioners.